7T2H image
Deposition Date 2021-12-04
Release Date 2022-12-07
Last Version Date 2025-05-14
Entry Detail
PDB ID:
7T2H
Title:
CryoEM structure of mu-opioid receptor - Gi protein complex bound to lofentanil (LFT)
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Mus musculus (Taxon ID: 10090)
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.20 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Guanine nucleotide-binding protein G(i) subunit alpha-1
Gene (Uniprot):GNAI1
Chain IDs:A
Chain Length:354
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Gene (Uniprot):GNB1
Chain IDs:B
Chain Length:344
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
Gene (Uniprot):GNG2
Chain IDs:C
Chain Length:71
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Mu-type opioid receptor
Gene (Uniprot):Oprm1
Chain IDs:E (auth: D)
Chain Length:356
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Molecule:scFv16
Chain IDs:D (auth: E)
Chain Length:259
Number of Molecules:1
Biological Source:Mus musculus
Ligand Molecules
Primary Citation
Insights into distinct signaling profiles of the mu OR activated by diverse agonists.
Nat.Chem.Biol. ? ? ? (2022)
PMID: 36411392 DOI: 10.1038/s41589-022-01208-y

Abstact

Drugs targeting the μ-opioid receptor (μOR) are the most effective analgesics available but are also associated with fatal respiratory depression through a pathway that remains unclear. Here we investigated the mechanistic basis of action of lofentanil (LFT) and mitragynine pseudoindoxyl (MP), two μOR agonists with different safety profiles. LFT, one of the most lethal opioids, and MP, a kratom plant derivative with reduced respiratory depression in animal studies, exhibited markedly different efficacy profiles for G protein subtype activation and β-arrestin recruitment. Cryo-EM structures of μOR-Gi1 complex with MP (2.5 Å) and LFT (3.2 Å) revealed that the two ligands engage distinct subpockets, and molecular dynamics simulations showed additional differences in the binding site that promote distinct active-state conformations on the intracellular side of the receptor where G proteins and β-arrestins bind. These observations highlight how drugs engaging different parts of the μOR orthosteric pocket can lead to distinct signaling outcomes.

Legend

Protein

Chemical

Disease

Primary Citation of related structures